

# Irritable Bowel Syndrome Treatment Market - 2025-2033

<https://marketpublishers.com/r/IF34D0CB81CBEN.html>

Date: April 2026

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: IF34D0CB81CBEN

## Abstracts

The Irritable Bowel Syndrome Treatment Market was valued at US\$ 3.93 billion in 2025 and is anticipated to reach US\$ 7.68 billion by 2033, at a CAGR of 0.088 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Irritable Bowel Syndrome Treatment Market.

This report delivers a comprehensive overview of the Irritable Bowel Syndrome Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Irritable Bowel Syndrome Treatment Market. The Irritable Bowel Syndrome Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Irritable Bowel Syndrome Treatment Market Scope:

Key Players

Procter & Gamble

Haleon Group of Companies.

Teva Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals, Inc.

AbbVie.

Salix Pharmaceuticals

Foundation Consumer Brands.

Kenvue Brands LLC.

Pfizer Inc.

Upsher-Smith Laboratories, LLC.

Sanofi

Bayer AG

Atlantis Consumer Healthcare Inc.

Alfasigma Group

Takeda Pharmaceutical Company Limited.

Ardelyx.

## Major Highlights

This report delivers a comprehensive overview of the Irritable Bowel Syndrome Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Irritable Bowel Syndrome Treatment Market. The Irritable Bowel Syndrome Treatment Market size,

estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

#### Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

#### Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

#### Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies



## Contents

### **1. MARKET INTRODUCTION AND SCOPE**

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### **2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS**

### **3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS**

- 3.1. Key Trends and Future Projections

### **4. SNIPPET BY DISEASE TYPE**

### **5. SNIPPET BY DRUG CLASS**

- 5.1. Snippet by Region

### **6. DYNAMICS**

- 6.1. Impacting Factors
  - 6.1.1. Drivers
    - 6.1.1.1. Rising Prevalence of Irritable Bowel Syndrome

### **7. RISING NOVEL PRODUCT APPROVALS**

### **8. RESTRAINTS**

- 8.1. Availability of Limited Treatment Options
  - 8.1.1. Underdiagnosis of IBS

### **9. OPPORTUNITIES**

- 9.1. Increasing Patient Awareness and Advocacy Programs
  - 9.1.1. Development of Microbiome-Based Therapies
  - 9.1.2. Impact Analysis

## **10. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK**

- 10.1. Market Leaders and Pioneers
  - 10.1.1. Emerging Pioneers and Prominent Players
  - 10.1.2. Established Leaders with the Largest Marketing Brand
  - 10.1.3. Market Leaders with Established Products
- 10.2. Latest Developments and Breakthroughs
- 10.3. Regulatory and Reimbursement Landscape
  - 10.3.1. North America
  - 10.3.2. Europe
  - 10.3.3. Asia Pacific
  - 10.3.4. Latin America
  - 10.3.5. Middle East & Africa
- 10.4. Porter's Five Forces Analysis
- 10.5. Supply Chain Analysis
- 10.6. Patent Analysis
- 10.7. SWOT Analysis
- 10.8. Pipeline Analysis
- 10.9. Epidemiology Analysis
- 10.10. Unmet Needs and Gaps
- 10.11. Recommended Strategies for Market Entry and Expansion
- 10.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 10.13. Pricing Analysis and Price Dynamics

## **11. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISEASE TYPE**

- 11.1. Introduction
  - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  - 11.1.2. Market Attractiveness Index, By Disease Type
- 11.2. IBS with Diarrhea (IBS-D) \*
  - 11.2.1. Introduction
  - 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. IBS with Constipation (IBS-C)
- 11.4. Mixed-Presentation IBS (IBS-M)
- 11.5. Undefined IBS (IBS-U)

## **12. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG**

## **CLASS**

### 12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

12.1.2. Market Attractiveness Index, By Drug Class

### 12.2. Antispasmodics

12.2.1. Introduction

12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 12.3. Antidiarrheal Medication

### 12.4. Laxatives

### 12.5. Antibiotics

### 12.6. Antidepressants

### 12.7. Fiber Supplements

### 12.8. Secretagogues

### 12.9. Others

## **13. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY REGION**

### 13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

13.1.2. Market Attractiveness Index, By Region

### 13.2. North America

13.2.1. Introduction

13.2.2. Key Region-Specific Dynamics

13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13.2.5.1. U.S.

13.2.5.2. Canada

13.2.5.3. Mexico

### 13.3. Europe

13.3.1. Introduction

13.3.2. Key Region-Specific Dynamics

13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13.3.5.1. Germany

13.3.5.2. U.K.

13.3.5.3. France

13.3.5.4. Spain

13.3.5.5. Italy

13.3.5.6. Rest of Europe

13.4. South America

13.4.1. Introduction

13.4.2. Key Region-Specific Dynamics

13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13.4.5.1. Brazil

13.4.5.2. Argentina

13.4.5.3. Rest of South America

13.5. Asia-Pacific

13.5.1. Introduction

13.5.2. Key Region-Specific Dynamics

13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13.5.5.1. China

13.5.5.2. India

13.5.5.3. Japan

13.5.5.4. South Korea

13.5.5.5. Rest of Asia-Pacific

13.6. Middle East and Africa

13.6.1. Introduction

13.6.2. Key Region-Specific Dynamics

13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

## **14. COMPETITIVE LANDSCAPE AND MARKET POSITIONING**

14.1. Competitive Overview and Key Market Players

14.2. Market Share Analysis and Positioning Matrix

14.3. Strategic Partnerships, Mergers & Acquisitions

14.4. Key Developments in Product Portfolios and Innovations

14.5. Company Benchmarking

## **15. COMPANY PROFILES**

- 15.1. Procter & Gamble\*
  - 15.1.1. Company Overview
  - 15.1.2. Product Portfolio
    - 15.1.2.1. Product Description
    - 15.1.2.2. Product Key Performance Indicators (KPIs)
    - 15.1.2.3. Historic and Forecasted Product Sales
    - 15.1.2.4. Product Sales Volume
  - 15.1.3. Financial Overview
    - 15.1.3.1. Company Revenue's
    - 15.1.3.2. Geographical Revenue Shares
    - 15.1.3.3. Revenue Forecasts
  - 15.1.4. Key Developments
    - 15.1.4.1. Mergers & Acquisitions
    - 15.1.4.2. Key Product Development Activities
    - 15.1.4.3. Regulatory Approvals, etc.
  - 15.1.5. SWOT Analysis
- 15.2. Haleon Group of Companies.
- 15.3. Teva Pharmaceutical Industries Ltd.
- 15.4. Ironwood Pharmaceuticals, Inc.
- 15.5. AbbVie.
- 15.6. Salix Pharmaceuticals
- 15.7. Foundation Consumer Brands.
- 15.8. Kenvue Brands LLC.
- 15.9. Pfizer Inc.
- 15.10. Upsher-Smith Laboratories, LLC.
- 15.11. Sanofi
- 15.12. Bayer AG
- 15.13. Atlantis Consumer Healthcare Inc.
- 15.14. Alfasigma Group
- 15.15. Takeda Pharmaceutical Company Limited.
- 15.16. Ardelyx. (\*LIST NOT EXHAUSTIVE)

## **16. APPENDIX**

- 16.1. About Us and Services
- 16.2. Contact Us

## I would like to order

Product name: Irritable Bowel Syndrome Treatment Market - 2025-2033

Product link: <https://marketpublishers.com/r/IF34D0CB81CBEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IF34D0CB81CBEN.html>